Cypherpunk Technologies Inc. Files Proxy Statement

TL;DR

CYPH files proxy statement - shareholder vote incoming.

AI Summary

Cypherpunk Technologies Inc. (formerly Leap Therapeutics, Inc. and Dekkun Corp) filed a Definitive Proxy Statement (DEFA14A) on November 19, 2025. The company, located in Cambridge, MA, is in the Pharmaceutical Preparations industry. This filing is a standard proxy statement, indicating it's related to shareholder matters.

Why It Matters

Proxy statements are crucial for shareholders as they provide information about company matters being voted on, such as director elections and executive compensation, influencing corporate governance.

Risk Assessment

Risk Level: low — This filing is a routine proxy statement and does not contain specific financial or operational risks.

Key Players & Entities

• CYPHERPUNK TECHNOLOGIES INC. (company) — Registrant
• LEAP THERAPEUTICS, INC. (company) — Former company name
• Dekkun Corp (company) — Former company name
• 47 THORNDIKE STREET SUITE B1-1 CAMBRIDGE, MA 02142 (company) — Business and mailing address
• 20251119 (date) — Filing date

FAQ

Filing Documents

• tm2531760d1_defa14a.htm (DEFA14A) — 9KB
• tm2531760d1_defa14aimg01.jpg (GRAPHIC) — 18KB
• tm2531760d1_defa14aimg02.jpg (GRAPHIC) — 215KB
• 0001104659-25-114086.txt ( ) — 333KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under §240.14a-12 Cypherpunk Technologies Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. YOUR VOTE IS IMPORTANT - PLEASE VOTE YOUR SHARES TODAY RE: Reminder of Special Meeting of Shareholders Dear Fellow Shareholder, We hope this message finds you well. We hope that you all saw the exciting announcement that Leap Therapeutics, Inc. is now Cypherpunk Technologies Inc., reflecting our expanded mission to support privacy enabling technologies, participate in the Zcash ecosystem, and acquire ZEC for our digital asset treasury. This is a reminder that we will hold a special meeting of stockholders on December 15, 2025, at 11:00 a.m. Eastern Time. Your Vote is Very Important! As a valued shareholder, your input plays a crucial role in shaping the future of our company, regardless of the size of your investment. Key Items Up for Vote: 1. Approval to increase authorized shares. To provide the company with flexibility for future financing and corporate activities, supporting strategic growth. 2. Approval of grant of authority to the Board to effect a reverse stock split, within a range of 1-for-5 to 1-for-20 To provide the company with flexibility for future financing and corporate activities, supporting strategic growth. 3. Adoption of the 2025 Equity Incentive Plan To continue attracting, retaining, and incentivizing talent which is critical to the company's progress. 4. Approval of the private placement issuance Approval is necessary to permit the company to issue shares in excess of 19.99% upon the exercise of certain warrants issued in the October 2025 private placement. The Board of Directors recommends a vote FOR all proposals as described in your proxy materials. If you have not yet voted, we strongly encourage you to do so as soon as possible by calling 888.742.1305 Monday through Friday, from 9 AM to 5 PM Eastern Time. Thank you for your continued support of Cypherpunk. Onward, Doug Onsi Chief Executive Officer and President

View Full Filing

View this DEFA14A filing on SEC EDGAR